Učitavanje...
ALK and NSCLC: Targeted therapy with ALK inhibitors
For many years treatment for advanced or metastatic non-small cell lung cancer (NSCLC) has employed chemotherapy regimens for patient care, with limited effect. Five-year survival rates for these patients are not encouraging. However, for a subgroup of these patients, there have been radical changes...
Spremljeno u:
| Glavni autori: | , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Faculty of 1000 Ltd
2011
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3206708/ https://ncbi.nlm.nih.gov/pubmed/22076124 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3410/M3-21 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|